That’s according to the Diabetes Patient Voice survey (DQ&A) — a third-party survey that evaluates U.S. diabetes patient satisfaction on a quarterly basis.
However, things are now looking up for the world’s largest medtech company in the diabetes tech space.
The old third-place ranking was for the previous-generation MiniMed 670G — before the company brought its next-generation MiniMed 780G system to the market.
The current iteration of MiniMed 780G uses the latest Guardian 4 technology and requires no fingersticks while in “SmartGuard” mode. It provides meal detection technology providing automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs.
MiniMed 780G with Guardian 4 offers insulin to account for when users forget to bolus or underestimate the number of carbs in their meal.
In the latest DQ&A survey of more than 6,000 patients with both type 1 and type 2 diabetes, the fourth-quarter 2024 survey, MiniMed 780G ranked first in patient satisfaction.
The system scored highest in satisfaction (64%) compared to competing pumps. That includes the Tandem t:slim X2/Dexcom G6 (57%) and Omnipod 5/G6 (44%). Results showed that satisfaction with the Guardian 4 sensor mirrors that of Dexcom and Abbott’s sensors, too. That came in at an all-time high following the introduction of MiniMed 780G.
“We’ve always been known for having strong outcomes, but we also had more of a burden profile,” Medtronic Diabetes VP, Global Marketing & Communications, Krista Sugerman told Drug Delivery Business News in a recent interview. “It just wasn’t quite as easy to use our systems. We’ve really been working toward that and we’re excited about our pipeline and being able to make it easier for people living with type 1 diabetes.”
Get the full story at our sister site, Drug Delivery Business News.